MDMA A New Hope for PTSD: The MAPS Public Benefit Corporation has advanced the use of MDMA, the active ingredient in ecstasy and molly, to treat post-traumatic stress disorder. The company requested that the FDA study MDMA-paired therapy. MDMA, known for its psychedelic properties, falls under the class of entactogens, producing experiences of emotional communion and openness.
MAPS has been at the forefront of studying the effects of MDMA in conjunction with therapy for treating PTSD. In 2017, the FDA granted breakthrough therapy designation to MDMA-assisted therapy, expediting its development and review due to preliminary clinical evidence indicating substantial improvement over existing therapies for a serious condition.
The recent application, filed by MAPS, marks a crucial phase in this ongoing research, with the FDA having 60 days to decide on accepting the new drug application for review. If accepted, the application might undergo a fast-tracked approval process.
Also Read: Cola Cure for Blocked Throats? Not So Fast, Holiday Revelers Discover
Clinical trials conducted by MAPS involving 90 and 104 participants demonstrated that MDMA significantly reduced symptoms and impairment associated with PTSD compared to a placebo. This submission is the culmination of over 30 years of clinical research, collaboration, and dedication, as stated by Amy Emerson, the CEO of MAPS.
Antidepressants and specialist cognitive-behavioral therapy are used to treat PTSD. These treatments are quite helpful for some, leaving a gap for those who don’t respond. MDMA is a schedule I drug under the Controlled Substances Act, meaning the US Drug Enforcement Administration does not allow its usage for treating PTSD. If the FDA approves it, it must be rescheduled.
Our Reader’s Queries
Can MDMA help with PTSD?
Although MDMA-assisted psychotherapy has proven to be a successful treatment for PTSD patients with a safe track record, the use of unregulated MDMA or administering it without a closely monitored psychotherapeutic setting can pose significant risks. It’s crucial to ensure that the therapy is conducted in a controlled environment to avoid any potential harm.
What is the breakthrough drug for PTSD?
In 2017, the F.D.A. gave MDMA-assisted therapy a “breakthrough therapy” status for treating PTSD. This designation speeds up the development of promising experimental drugs. Similarly, psilocybin-assisted therapy for treatment-resistant depression was granted breakthrough status in 2018.
Which drug has shown significant promise for the treatment of PTSD?
PTSD symptoms can manifest months or even years after a traumatic event. A recent study conducted by Stanford University revealed that a group of veterans diagnosed with mild traumatic brain injury experienced significant improvements in their daily function and mental health symptoms after undergoing treatment with ibogaine, a psychedelic drug. This promising development offers hope for those struggling with PTSD and related conditions.
Is MDMA-assisted psychotherapy for PTSD approved by the FDA?
In a recent press statement, Rick Doblin, the founder and president of MAPS, expressed his gratitude towards the numerous therapists, participants, and donors who have contributed towards the success of MDMA-assisted therapy for PTSD. Thanks to their combined efforts, the therapy is now on track to be considered for approval by the FDA in 2024. This achievement is a testament to the power of collaboration and the impact that can be made when individuals come together for a common cause.